Stomatitis with aphthous-type ulcers in a patient treated with a mechanistic (previously called mammalian) target of rapamycin (mTOR) inhibitor
(A) Multiple mIAS of the soft palate with mTOR inhibitor (everolimus).
(B) Typical mIAS with an erythematous halo onnonkeratinized mucosa (everolimus).
(C) A major aphthous-like ulceration with everolimus (mIAS).
Reprinted by permission from Springer: Supportive Care in Cancer. Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer 2017; 25:1713. Copyright © 2017.
https://www.springer.com/journal/520.
